TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05821517
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.
Study: NCT06364696
Drug: ASP4396
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT04456517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine-matched placebo tablet
Study: NCT04992962
Drug: CBD/CBN
Approvals — FDA: no, EMA: no, PMDA: no
Description: A water-soluble sublingual tablet containing 10 mg of CBD and 10 mg of CBN.
Study: NCT04992962
Drug: CBD/THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: A water-soluble sublingual tablet containing 10 mg of CBD and 5 mg of THC.
Study: NCT04992962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inactive compound.
Study: NCT05669001
Drug: TAC
Normalized name: TAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT05669001
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppression Therapy
Study: NCT06308913
Drug: INCB081776
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB081776 will be given orally on a daily basis. The highest safe/tolerable dose and schedule will be established by the ongoing phase 1 clinical trial of INCB081776 plus INCBMGA00012 (NCT03522142), which is 120 mg daily.
Study: NCT05625399
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04838717
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral: at a dose of 100 mg bid for 14 days
Study: NCT06343792
Drug: RLS-0071
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.
Study: NCT05437250
Drug: Non interventional study
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLL patients initiated with acalabrutinib at their physician's discretion between January 1, 2021 and December 31, 2022 . Secondary data collection
Study: NCT06555783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet containing placebo for once daily administration
Study: NCT05681572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
Study: NCT06235749
Drug: Calcium Gluconate 10%
Normalized name: Calcium Gluconate 10% Solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Calcium Gluconate 10% IV following umbilical cord clamping
Study: NCT05491356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution, intra-catheter administration, sterile
Study: NCT06272370
Drug: Inhaled Steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy
Study: NCT06272370
Drug: Azithromycin Pill
Normalized name: azithromycin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects
Study: NCT05974345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
Study: NCT05090800
Drug: Definity contrast during ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo an ultrasound contrast evaluation of both kidneys. This will include placement of an intravenous (IV) catheter in a vein and the delivery of Definity ultrasound contrast agent through the IV. Imaging will be completed for each kidney. The proposed total dose for adult patients will not exceed 20 microliters/kilograms (kg). Each individual dose not to exceed 10 microliters/kg. At initiation of patient studies, the dose will start at 10 microliters/kg for the first injection and a second 10 microliters/kg dose to evaluate the contralateral kidney. However, if ultrasound findings in patient studies demonstrate a dose that is too high (unable to make accurate ultrasound assessment), the dose will be reduced.
Study: NCT05362409
Drug: 5 Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid \[5-ALA\] administered orally 20 mg/kg every 4 weeks
Study: NCT06188702
Drug: S095035
Approvals — FDA: no, EMA: no, PMDA: no
Description: S095035 will be taken orally once daily in 28-day cycle.
Study: NCT05587309
Drug: BLI5100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally via tablet
Study: NCT04754945
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT06338826
Drug: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from~* NNRTI = efavirenz, rilpivirine, etravirine, doravirine~* PI/r = atazanavir/r ou darunavir/r~* INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir
Study: NCT04734197
Drug: SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combination of a topical immunosuppressant and a topical corticosteroid solution
Study: NCT04734197
Drug: Mycophenolic Acid 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical immunosuppressant
Study: NCT04734197
Drug: Mycophenolic Acid 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical immunosuppressant
Study: NCT04734197
Drug: Placebo Comparator: Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical vehicle solution
Study: NCT04153422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.
Study: NCT06075745
Drug: CMV-MVA Triplex
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage used will be 5.0 x 10\^8 pfu, administered under sterile conditions intramuscularly. The CMV-MVA Triplex vaccine lots range in titre from 5.0 to 9.0 x 10\^8 pfu/mL in a supplied volume of 1.0 mL
Study: NCT05377333
Drug: LY3457263
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05377333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06520540
Drug: HDM1002 100 mg QD 12weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)
Study: NCT06520540
Drug: HDM1002 200 mg QD 12weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)
Study: NCT06520540
Drug: HDM1002 400 mg QD 12weeks，Q 2W for titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration
Study: NCT06520540
Drug: HDM1002 400 mg QD 12weeks，Q 3W for titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration
Study: NCT04146298
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered prior to cell infusion.
Study: NCT05116527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo THC - marijuana flower with no THC content
Study: NCT04767308
Drug: Cyclophosphamide, fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day on days -4, -3 and -2
Study: NCT06367218
Drug: opioid-free strategy
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine was used for induction and maintenance of anesthesia
Study: NCT06093841
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to package insert
Study: NCT05304936
Drug: HCW9218
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifunctional TGF-β antagonist/IL-15 protein complex
Study: NCT06442137
Drug: Chazhu Xiaozhi decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Below is the composition of Chazhu Xiaozhi decoction: Camellia Sinensis Radix 15g, Atractylodis Rhizoma 15g, Herba Gynostemmatis Pentaphylli 15g, Ilicis Cornutae Folium 15g, Alismatis Rhizoma 9g, Nelumbinis Folium 6g, Crataegi Fructus 6g, Polygoni Orientalis Fructus 3g.
Study: NCT06442137
Drug: Control placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control placebo is a ten-fold dilution of the Chazhu Xiaozhi decoction, supplemented with colorants and bittering agents to mimic the appearance and color of the treatment drug.
Study: NCT04383119
Drug: No Intervention: Observational Cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according clinical practice
Study: NCT06073119
Drug: SAR441566
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT06073119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT06260527
Drug: ARTS-011
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single ascending dose (SAD): 3mg, 10mg, 20mg, 40mg, and 60mg. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Food effect study: single dose of ARTS-011 under the fasting and high-fat meal.
Study: NCT06260527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days.
Study: NCT05872477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
Study: NCT05532046
Drug: BAY2413555 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY2413555 Dose 1
Study: NCT05532046
Drug: BAY2413555 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY2413555 Dose 2
Study: NCT05532046
Drug: Placebo to BAY2413555
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to BAY2413555
Study: NCT05660421
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth or by vein
Study: NCT05727384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg, subcutaneous injection, every 4 weeks for 24 weeks
Study: NCT06310785
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the opioid group, sufentanil was used as an analgesic during anesthesia induction and remifentanil was used as an analgesic during anesthesia maintenance.
Study: NCT06227832
Drug: KP-001
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Description: KP-001
Study: NCT06227832
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral doses of 1000 mg Clarithromycin
Study: NCT06128629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl) by IV infusion
Study: NCT06039020
Drug: Anti-human thymocyte immunoglobulin, equine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be slowly administered by intravenous drip infusion once daily. The duration of treatment should be 4 days.
Study: NCT06545175
Drug: Intracochlear application of VSF1.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: During cochlear implant operation, patients receive intracochlear VSF1.01 prior to insertion of the electrode array.
Study: NCT05166343
Drug: Epinephrine Injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s) and/or pre-filled syringe (exact dose).
Study: NCT06503094
Drug: CD19&CD20 bispecific CAR-T cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive CD19\&CD20 bispecificCAR-T cells by intravenous infusion on day 0.
Study: NCT05704985
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent or combination of not more than two
Study: NCT05904626
Drug: ELGN-2112
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
Study: NCT05904626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo formulation consisting of the same inactive ingredients as ELGN-2112.
Study: NCT04177004
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04774003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1
Study: NCT05346835
Drug: Cilta-cel OOS Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) will be provided as a one-time administration as an intravenous infusion.
Study: NCT05857163
Drug: Clarithromycin placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID, taken orally within half an hour after breakfast and dinner.
Study: NCT05857163
Drug: Clarithromycin tablets
Normalized name: Clarithromycin Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg, BID, taken orally within half an hour after breakfast and dinner.
Study: NCT05571878
Drug: Saline nasal spray
Normalized name: Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be given an intranasal saline placebo (0.8 mL) in order to establish baseline brain insulin signalling via MRI based assay
Study: NCT06499090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive orally the night before surgery the study medication and daily up to two weeks after placebo tablet
Study: NCT05418868
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuPH20 will be administered.
Study: NCT06517797
Drug: S1B-509
Approvals — FDA: no, EMA: no, PMDA: no
Description: S1B-509 has multiple neurotransmitter activities
Study: NCT05998928
Drug: Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 both on three consecutive days during D-7 to D-3~BCMA-GPRC5D CAR-T Cells on day 0
Study: NCT06126653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titratable, liquid formulation, taken orally.
Study: NCT06349759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing
Study: NCT05074602
Drug: SHR8008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral
Study: NCT06127225
Drug: Proliverenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily
Study: NCT06127225
Drug: Placebo caplets of Proliverenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 caplets of Proliverenol Placebo daily
Study: NCT05811234
Drug: CAL/BDP PAD Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: As provided in real-world clinical practice.
Study: NCT05676489
Drug: [F-18]MeFAMP PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
Study: NCT05636514
Drug: Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
Normalized name: decitabine/cedazuridine 35 mg-100 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.
Study: NCT04971395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2 or 4 mg/kg
Study: NCT06106945
Drug: AZD0305
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0305
Study: NCT06460948
Drug: Norethindrone Acetate-Ethinyl Estradiol
Normalized name: norethindrone acetate-ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-progestin will be given to participants in both cohorts, arginine-vasopressin deficiency cohort and healthy control cohort.
Study: NCT04968210
Drug: Hyperpolarized 13C-pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of hyperpolarized 13C-pyruvate to assess metabolic remodeling in PAH
Study: NCT05763121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of placebo tablet
Study: NCT06152471
Drug: SPC-flakes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aktive drug
Study: NCT06152471
Drug: Salovum
Normalized name: Medical Food Oral Powder for Suspension [SALOVUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug
Study: NCT06152471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drugs
Study: NCT05086315
Drug: SAR443579
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for solution for infusion; by IV infusion
Study: NCT06168409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matching baxdrostat, administered orally, once daily (QD).
Study: NCT05692180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution will be administered SC to the patients.
Study: NCT06253221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06045247
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT06422767
Drug: Bepirovirsen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen will be administered.
Study: NCT06422767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT06453083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be dispensed to the participants for 6-days.
Study: NCT06330077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment administration
Study: NCT05041647
Drug: 25:1 CBD/THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 1 dose (1 mL) of HIGH CBD~* 50 mg/ml CBD and 2 mg/ ml THC
Study: NCT05041647
Drug: 5:1 CBD/THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 1 dose (1 mL) of LOW CBD~* 10 mg/ml CBD and 2 mg/ ml THC
Study: NCT04831684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be getting placebo for 8 days of dosing.
Study: NCT04936841
Drug: NKTR-214
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bempegaldesleukin (NKTR-214) is an immunotherapeutic protein prodrug specifically designed to activate the patient's immune system for the treatment of cancer by providing a controlled, sustained signal to the interleukin-2 (IL-2) receptor pathway (pharmacological classification: immunostimulatory interleukin cytokine)
Study: NCT04936841
Drug: anti-PD-1 therapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: immunotherapy drug, monoclonal antibody
Study: NCT06295328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
Study: NCT05279651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
Study: NCT04998487
Drug: LY3471851
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04141995
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU will be given as a 46 hour continuous IV infusion
Study: NCT04141995
Drug: Calcium Leucovorin
Normalized name: Calcium leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection over 90 minutes